Russian State Duma Considers Ban on Sale of E-Cigarettes

Aug.30.2024
Russian State Duma Considers Ban on Sale of E-Cigarettes
Russian State Duma may consider bipartisan bill to ban e-cigarettes nationwide, citing potential health risks including new disease similar to COVID-19.

According to a report by Eadaily on August 30th, the Russian State Duma may consider a bipartisan bill during its autumn session that aims to completely ban the sale of e-cigarettes in Russia.


This information was revealed by Yaroslav Nilov, chairman of the State Duma's Committee on Social Policy and member of the LDPR, one of the drafters of the bill.


Previously, the Russian Ministry of Health warned that e-cigarettes and e-cigarette liquids may trigger a new disease. The department pointed out that e-cigarettes can cause a disease called EVALI, which presents symptoms similar to the novel coronavirus and is due to acute lung injury caused by the use of e-cigarettes.


Nilovf stated that


This initiative is bipartisan, and we are hopeful that it will be discussed this fall.


He added that it is necessary to legislate to ban e-cigarettes as soon as possible before they become fully integrated into people's daily lives.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02
Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Ahead of World No Tobacco Day, a Nature Health Comment by Robert Beaglehole, Ruth Bonita and Tikki Pang argues that regulated smoke-free nicotine products could help accelerate the global decline in smoking. The authors propose a “smoke-free 2040” goal and call for risk-proportionate regulation distinguishing cigarettes from lower-risk nicotine alternatives.
News
May.20
American Snuff Expands Manufacturing Hiring as Reynolds American Builds Future-Ready Operations
American Snuff Expands Manufacturing Hiring as Reynolds American Builds Future-Ready Operations
Reynolds American said American Snuff Company will add more than 50 manufacturing roles at its Clarksville, Tennessee facility as part of its wider U.S. manufacturing investment plan. The company said the hiring is one of the latest developments under its plan to invest more than USD 3.2 billion across U.S. operations by 2030.
Mar.27 by 2FIRSTS.ai
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches
The U.S. Food and Drug Administration issued guidance on May 8, 2026, titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” The document describes FDA enforcement policies for certain electronic nicotine delivery system products and nicotine pouch products marketed without premarket authorization.
May.09 by 2FIRSTS.ai
Geneva Court Annuls Ban on Disposable E-Cigarette Sales, Says Power Lies With Federal Authorities
Geneva Court Annuls Ban on Disposable E-Cigarette Sales, Says Power Lies With Federal Authorities
The Geneva Court of Justice on Tuesday upheld appeals filed by four associations and companies active in the tobacco trade and annulled the Geneva legal provision banning the sale of disposable e-cigarettes, commonly known as “puffs.”
Apr.30 by 2FIRSTS.ai
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17